-$0.43 Earnings Per Share Expected for Sol Gel Technologies Ltd (NASDAQ:SLGL) This Quarter

Equities research analysts expect Sol Gel Technologies Ltd (NASDAQ:SLGL) to report ($0.43) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Sol Gel Technologies’ earnings, with estimates ranging from ($0.62) to ($0.29). Sol Gel Technologies posted earnings of ($0.37) per share in the same quarter last year, which would suggest a negative year over year growth rate of 16.2%. The firm is expected to announce its next earnings report on Wednesday, November 11th.

According to Zacks, analysts expect that Sol Gel Technologies will report full year earnings of ($1.57) per share for the current fiscal year, with EPS estimates ranging from ($1.85) to ($1.34). For the next financial year, analysts anticipate that the firm will report earnings of ($1.76) per share, with EPS estimates ranging from ($2.09) to ($1.49). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Sol Gel Technologies.

Sol Gel Technologies (NASDAQ:SLGL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.01. Sol Gel Technologies had a negative net margin of 210.73% and a negative return on equity of 46.18%.

Several brokerages have recently issued reports on SLGL. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Sol Gel Technologies in a report on Tuesday, June 30th. Raymond James reiterated a “buy” rating on shares of Sol Gel Technologies in a research note on Tuesday, September 1st. Finally, Zacks Investment Research downgraded shares of Sol Gel Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $22.05.

NASDAQ SLGL traded up $0.25 on Wednesday, reaching $7.80. The stock had a trading volume of 17,702 shares, compared to its average volume of 46,075. The company has a current ratio of 9.94, a quick ratio of 9.94 and a debt-to-equity ratio of 0.02. Sol Gel Technologies has a 1 year low of $5.00 and a 1 year high of $21.00. The business has a 50 day moving average price of $7.70 and a 200 day moving average price of $7.95. The company has a market capitalization of $159.04 million, a price-to-earnings ratio of -5.86 and a beta of 1.44.

Several hedge funds have recently modified their holdings of SLGL. Raymond James & Associates lifted its holdings in Sol Gel Technologies by 18.8% in the 1st quarter. Raymond James & Associates now owns 41,586 shares of the company’s stock worth $294,000 after purchasing an additional 6,581 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Sol Gel Technologies by 20.9% in the first quarter. Steward Partners Investment Advisory LLC now owns 8,660 shares of the company’s stock worth $61,000 after buying an additional 1,500 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Sol Gel Technologies in the first quarter worth $117,000. Morgan Stanley boosted its holdings in shares of Sol Gel Technologies by 318.0% during the 1st quarter. Morgan Stanley now owns 17,437 shares of the company’s stock worth $123,000 after buying an additional 13,265 shares during the period. Finally, Invesco Ltd. acquired a new position in Sol Gel Technologies in the 1st quarter valued at $567,000. 32.08% of the stock is currently owned by institutional investors and hedge funds.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Recommended Story: Can systematic risk be avoided?

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sol Gel Technologies (NASDAQ:SLGL)

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.